SCHEMBL968990

SCHEMBL968990

O=C(CN1CCc2c(sc3nc(N4CCOCC4)ccc23)C1)N1CCN(C2CCC2)CC1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.41
ALDH1A1 P00352 4/20 0.41
RECQL P46063 1/20 0.41
PARP1 P09874 1/20 0.41
HRH3 Q9Y5N1 10/20 0.38
HPGD P15428 2/20 0.35
HSD17B10 Q99714 2/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35
TP53 P04637 1/20 0.35
ALOX15 P16050 1/20 0.35
MAPK1 P28482 1/20 0.35
CBX7 O95931 1/20 0.35
CDYL2 Q8N8U2 1/20 0.35
CDYL Q9Y232 1/20 0.35
CDY1; CDY1B Q9Y6F8 1/20 0.35
MEN1 O00255 1/20 0.35
PIK3CA P42336 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL971043 0.93 PARP1 (0.43) KDM4EALDH1A1RECQLPARP1HRH3
SCHEMBL969094 0.84 PARP1 (0.44) KDM4EALDH1A1PARP1HRH3HPGD
SCHEMBL13985865 0.82 PARP1 (0.43) KDM4EALDH1A1PARP1HRH3HPGD
SCHEMBL968525 0.82 PARP1 (0.43) KDM4EALDH1A1PARP1HRH3HPGD
SCHEMBL970335 0.82 MCHR1 (0.42) KDM4EALDH1A1RECQLPARP1HRH3
SCHEMBL971614 0.81 TMEM97 (0.38) KDM4EALDH1A1PARP1HRH3HPGD
SCHEMBL12920055 0.80 PARP1 (0.41) KDM4EALDH1A1PARP1HRH3HPGD
SCHEMBL1018360 0.80 KDM4E (0.46) KDM4EALDH1A1RECQLPARP1HRH3
SCHEMBL966767 0.78 PARP1 (0.40) KDM4EALDH1A1PARP1HRH3HPGD
SCHEMBL969371 0.78 PARP1 (0.40) KDM4EALDH1A1PARP1HRH3HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
WO-2009003003-A2 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 KDM4E 3037/4885ALDH1A1 812/4885RECQL 1372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.